Kodiak Sciences Earns Buy Rating from HC Wainwright

Got story updates? Submit your updates here. ›

Kodiak Sciences (NASDAQ:KOD), a clinical-stage biopharmaceutical company focused on retinal diseases, has received a "buy" rating and increased price target from HC Wainwright. The analysts cited positive results from the company's GLOW2 Phase 3 trial for its lead drug candidate KSI-301, an anti-VEGF antibody biopolymer conjugate for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Why it matters

The positive GLOW2 data, along with an earlier successful Phase 3 study, sets Kodiak up to potentially file for regulatory approval of KSI-301, which could be a significant advancement in the treatment of serious retinal diseases like wet AMD and DME. Strong clinical results and analyst support could also boost investor confidence and the company's stock price.

The details

In the GLOW2 trial, 62.5% of patients treated with KSI-301 achieved a ≥2-step improvement in Diabetic Retinopathy Severity Score (DRSS) compared to just 3.3% in the sham control group. These results, combined with positive data from the earlier GLOW1 study, are expected to support Kodiak's planned Biologics License Application (BLA) submission for KSI-301. HC Wainwright raised its price target on Kodiak shares from $38 to $58, representing a potential upside of nearly 46% from the previous close.

• Kodiak Sciences announced the positive GLOW2 topline results on March 27, 2026.
• The company is expected to file a BLA for KSI-301 following the successful Phase 3 studies.

What they’re saying

What’s next

The company is expected to file a Biologics License Application (BLA) for KSI-301 with regulatory authorities following the successful Phase 3 clinical trials.